<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477332</url>
  </required_header>
  <id_info>
    <org_study_id>CQGE031C2201</org_study_id>
    <secondary_id>2014-005559-16</secondary_id>
    <nct_id>NCT02477332</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and
      safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic
      Spontaneous Urticaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2015</start_date>
  <completion_date type="Actual">June 12, 2017</completion_date>
  <primary_completion_date type="Actual">November 2, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Hives Response (HSS7=0)</measure>
    <time_frame>Week 12</time_frame>
    <description>The primary objective was to establish the dose-response relationship of ligelizumab (24, 72 and 240 mg every 4 weeks) with respect to achievement of complete hives response (HSS7=0) at Week 12 and select an appropriate dose (or range of doses) which is likely to be superior to omalizumab at the highest approved dose (300 mg every 4 weeks).
Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the preceding 7 days, with a possible range of 0 - 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)
To confirm an overall dose-response signal based on MCP-Mod, and to estimate the minimal ligelizumab dose that shows a relevant superior effect over omalizumab, based on the selected dose response model, the lowest ligelizumab dose that provides a response rate 15% higher than the response of omalizumab 300 mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days</measure>
    <time_frame>Week 12</time_frame>
    <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete hives response defined as HSS7 = 0.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days</measure>
    <time_frame>Week 12</time_frame>
    <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HSS7=0 Response: at Week 20 Measured Over 7 Days</measure>
    <time_frame>Week 20</time_frame>
    <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete hives response defined as HSS7 = 0.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hives Severity Score (HSS7) at Week 20 Measured Over 7 Days</measure>
    <time_frame>Week 20</time_frame>
    <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Itch Severity Score (ISS7) at Week 12 Measured Over 7 Days</measure>
    <time_frame>Week 12</time_frame>
    <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Itch Severity Score (ISS7) at Week 20 Measured Over 7 Days</measure>
    <time_frame>Week 20</time_frame>
    <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urticaria Activity Score (UAS7) at Week 12 Measured Over 7 Days</measure>
    <time_frame>Week 12</time_frame>
    <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urticaria Activity Score (UAS7) at Week 20 Measured Over 7 Days</measure>
    <time_frame>Week 20</time_frame>
    <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Urticaria Activity Score Response (UAS7=0) Rate at Week 12 Measured Over 7 Days</measure>
    <time_frame>Week 12</time_frame>
    <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.
Complete urticaria activity response is defined as UAS7 = 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UAS7=0 Response: at Week 20 Measured Over 7 Days</measure>
    <time_frame>Week 20</time_frame>
    <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.
Complete urticaria activity response is defined as UAS7 = 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Itch Response (ISS7=0) Rate at Week 12 Measured Over 7 Days</measure>
    <time_frame>Week 12</time_frame>
    <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete itch response defined as ISS7 = 0.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISS7=0 Response: at Week 20 Measured Over 7 Days</measure>
    <time_frame>Week 20</time_frame>
    <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete itch response defined as ISS7 = 0.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">382</enrollment>
  <condition>Chronic Spontaneous Urticaria</condition>
  <arm_group>
    <arm_group_label>QGE031 24 mg s.c. q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QGE031 72 mg s.c. q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QGE031 240 mg s.c. q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omalizumab 300 mg s.c. q4w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo s.c. q4w</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo injection subcutaneous every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QGE031 120 mg s.c. s.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ligelizumab 120 mg injection subcutaneous single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QGE031</intervention_name>
    <arm_group_label>QGE031 120 mg s.c. s.d.</arm_group_label>
    <arm_group_label>QGE031 24 mg s.c. q4w</arm_group_label>
    <arm_group_label>QGE031 240 mg s.c. q4w</arm_group_label>
    <arm_group_label>QGE031 72 mg s.c. q4w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <arm_group_label>Omalizumab 300 mg s.c. q4w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo s.c. q4w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of chronic spontaneous urticaria for at least 6 months

          -  Diagnosis of chronic spontaneous urticaria refractory to standard of care at time of
             randomization

        Exclusion Criteria:

          -  Clearly defined underlying etiology for chronic urticaria other than chronic
             spontaneous urticaria

          -  Evidence of parasitic infection

          -  Any other skin disease with chronic itching

          -  Previous treatment with omalizumab or QGE031

          -  Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or
             epinephrine

          -  History of anaphylaxis

          -  History or current diagnosis of ECG abnormalities indicating significant risk of
             safety for patients participating in the study

          -  History of hypersensitivity to any of the study drugs or its components of similar
             chemical classes

          -  Pregnant or nursing (lactating) women

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waldorf</city>
        <state>Maryland</state>
        <zip>20602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4V 1R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>GR</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haidari Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiroshima city</city>
        <state>Hiroshima</state>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Obihiro-city</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>221-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kamimashi-gun</city>
        <state>Kumamoto</state>
        <zip>861-3101</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama-city</city>
        <state>Saitama</state>
        <zip>330-0854</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Machida-city</city>
        <state>Tokyo</state>
        <zip>194-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141 8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan Republic</state>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>194223</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St.-Petersburg</city>
        <zip>195112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sant Joan Despi</city>
        <state>Barcelona</state>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2015</study_first_posted>
  <results_first_submitted>June 5, 2018</results_first_submitted>
  <results_first_submitted_qc>September 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QGE031</keyword>
  <keyword>ligelizumab</keyword>
  <keyword>omalizumab</keyword>
  <keyword>chronic</keyword>
  <keyword>spontaneous</keyword>
  <keyword>urticaria</keyword>
  <keyword>adults</keyword>
  <keyword>CSU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>574 subjects screened; 382 subjects randomized; 338 (88.5%) subjects completed treatment epoch; 349 (91.4%) subjects entered follow-up phase and 320 (83.8%) completed the follow-up epoch</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>QGE031 24 mg s.c. q4w</title>
          <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>QGE031 72 mg s.c. q4w</title>
          <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>QGE031 240 mg s.c. q4w</title>
          <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="P4">
          <title>Omalizumab 300 mg s.c. q4w</title>
          <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="P5">
          <title>Placebo s.c. q4w</title>
          <description>placebo injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="P6">
          <title>QGE031 120 mg s.c. s.d.</title>
          <description>ligelizumab 120 mg injection subcutaneous single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="85"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered.</population>
      <group_list>
        <group group_id="B1">
          <title>QGE031 24 mg s.c. q4w</title>
          <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>QGE031 72 mg s.c. q4w</title>
          <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>QGE031 240 mg s.c. q4w</title>
          <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Omalizumab 300 mg s.c. q4w</title>
          <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="B5">
          <title>Placebo s.c. q4w</title>
          <description>placebo injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="B6">
          <title>QGE031 120 mg s.c. s.d.</title>
          <description>ligelizumab 120 mg injection subcutaneous single dose</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="85"/>
            <count group_id="B4" value="85"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="42"/>
            <count group_id="B7" value="382"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="360"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="14.36"/>
                    <measurement group_id="B2" value="44.3" spread="12.38"/>
                    <measurement group_id="B3" value="42.9" spread="10.51"/>
                    <measurement group_id="B4" value="41.8" spread="13.06"/>
                    <measurement group_id="B5" value="45.4" spread="11.22"/>
                    <measurement group_id="B6" value="42.4" spread="14.54"/>
                    <measurement group_id="B7" value="43.3" spread="12.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="286"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Hives Response (HSS7=0)</title>
        <description>The primary objective was to establish the dose-response relationship of ligelizumab (24, 72 and 240 mg every 4 weeks) with respect to achievement of complete hives response (HSS7=0) at Week 12 and select an appropriate dose (or range of doses) which is likely to be superior to omalizumab at the highest approved dose (300 mg every 4 weeks).
Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the preceding 7 days, with a possible range of 0 - 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)
To confirm an overall dose-response signal based on MCP-Mod, and to estimate the minimal ligelizumab dose that shows a relevant superior effect over omalizumab, based on the selected dose response model, the lowest ligelizumab dose that provides a response rate 15% higher than the response of omalizumab 300 mg.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo s.c. q4w</title>
            <description>placebo injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>QGE031 120 mg s.c. s.d.</title>
            <description>ligelizumab 120 mg injection subcutaneous single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Hives Response (HSS7=0)</title>
          <description>The primary objective was to establish the dose-response relationship of ligelizumab (24, 72 and 240 mg every 4 weeks) with respect to achievement of complete hives response (HSS7=0) at Week 12 and select an appropriate dose (or range of doses) which is likely to be superior to omalizumab at the highest approved dose (300 mg every 4 weeks).
Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the preceding 7 days, with a possible range of 0 - 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)
To confirm an overall dose-response signal based on MCP-Mod, and to estimate the minimal ligelizumab dose that shows a relevant superior effect over omalizumab, based on the selected dose response model, the lowest ligelizumab dose that provides a response rate 15% higher than the response of omalizumab 300 mg.</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" lower_limit="17.2" upper_limit="46.1"/>
                    <measurement group_id="O2" value="51.2" lower_limit="40.0" upper_limit="62.3"/>
                    <measurement group_id="O3" value="42.4" lower_limit="31.7" upper_limit="53.6"/>
                    <measurement group_id="O4" value="25.9" lower_limit="17.0" upper_limit="36.5"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O6" value="19.0" lower_limit="8.6" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Target dose was based on this estimated dose response. The 60% CI included the 20 - 80th percentile of target dose estimated in the bootstrap samples.</method_desc>
            <param_type>Estimated target dose</param_type>
            <param_value>32.5</param_value>
            <ci_percent>60</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.5</ci_lower_limit>
            <ci_upper_limit>42.5</ci_upper_limit>
            <estimate_desc>Min dose with effect size &gt;15%</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days</title>
        <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete hives response defined as HSS7 = 0.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Hives Response (HSS7=0) Rate at Week 12 Measured Over 7 Days</title>
          <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete hives response defined as HSS7 = 0.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days</title>
        <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hives Severity Score (HSS7) at Week 12 Measured Over 7 Days</title>
          <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.75" lower_limit="-15.75" upper_limit="-2.50"/>
                    <measurement group_id="O2" value="-15.50" lower_limit="-20.00" upper_limit="-6.00"/>
                    <measurement group_id="O3" value="-13.50" lower_limit="-19.00" upper_limit="-9.00"/>
                    <measurement group_id="O4" value="-11.00" lower_limit="-16.50" upper_limit="-4.50"/>
                    <measurement group_id="O5" value="-6.50" lower_limit="-13.00" upper_limit="-2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HSS7=0 Response: at Week 20 Measured Over 7 Days</title>
        <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete hives response defined as HSS7 = 0.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
        <time_frame>Week 20</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>HSS7=0 Response: at Week 20 Measured Over 7 Days</title>
          <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete hives response defined as HSS7 = 0.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hives Severity Score (HSS7) at Week 20 Measured Over 7 Days</title>
        <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
        <time_frame>Week 20</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hives Severity Score (HSS7) at Week 20 Measured Over 7 Days</title>
          <description>Hives Severity Score (HSS) is on a scale of 0 to 3. A weekly score (HSS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Hives Severity Score scale:
0 - None
- Mild (1-6 hives/12 hours)
- Moderate (7-12 hives/12 hours)
- Severe (&gt;12 hives/12 hours)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.00" lower_limit="-12.50" upper_limit="-3.50"/>
                    <measurement group_id="O2" value="-16.50" lower_limit="-20.50" upper_limit="-6.83"/>
                    <measurement group_id="O3" value="-14.00" lower_limit="-19.50" upper_limit="-9.00"/>
                    <measurement group_id="O4" value="-11.00" lower_limit="-16.00" upper_limit="-4.25"/>
                    <measurement group_id="O5" value="-7.50" lower_limit="-13.50" upper_limit="-2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Itch Severity Score (ISS7) at Week 12 Measured Over 7 Days</title>
        <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Itch Severity Score (ISS7) at Week 12 Measured Over 7 Days</title>
          <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.50" lower_limit="-12.75" upper_limit="-3.50"/>
                    <measurement group_id="O2" value="-9.50" lower_limit="-14.50" upper_limit="-6.00"/>
                    <measurement group_id="O3" value="-9.00" lower_limit="-14.00" upper_limit="-4.50"/>
                    <measurement group_id="O4" value="-8.00" lower_limit="-11.50" upper_limit="-4.50"/>
                    <measurement group_id="O5" value="-5.50" lower_limit="-8.50" upper_limit="-2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Itch Severity Score (ISS7) at Week 20 Measured Over 7 Days</title>
        <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
        <time_frame>Week 20</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Itch Severity Score (ISS7) at Week 20 Measured Over 7 Days</title>
          <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.00" lower_limit="-11.00" upper_limit="-2.00"/>
                    <measurement group_id="O2" value="-10.25" lower_limit="-14.00" upper_limit="-6.50"/>
                    <measurement group_id="O3" value="-10.00" lower_limit="-14.00" upper_limit="-5.50"/>
                    <measurement group_id="O4" value="-8.83" lower_limit="-11.50" upper_limit="-3.50"/>
                    <measurement group_id="O5" value="-5.00" lower_limit="-9.50" upper_limit="-2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urticaria Activity Score (UAS7) at Week 12 Measured Over 7 Days</title>
        <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urticaria Activity Score (UAS7) at Week 12 Measured Over 7 Days</title>
          <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.50" lower_limit="-26.75" upper_limit="-6.25"/>
                    <measurement group_id="O2" value="-26.50" lower_limit="-33.00" upper_limit="-12.00"/>
                    <measurement group_id="O3" value="-21.75" lower_limit="-32.50" upper_limit="-14.00"/>
                    <measurement group_id="O4" value="-19.00" lower_limit="-29.00" upper_limit="-8.50"/>
                    <measurement group_id="O5" value="-12.00" lower_limit="-21.00" upper_limit="-6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urticaria Activity Score (UAS7) at Week 20 Measured Over 7 Days</title>
        <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.</description>
        <time_frame>Week 20</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urticaria Activity Score (UAS7) at Week 20 Measured Over 7 Days</title>
          <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Score on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.00" lower_limit="-23.00" upper_limit="-7.00"/>
                    <measurement group_id="O2" value="-27.00" lower_limit="-33.00" upper_limit="-15.00"/>
                    <measurement group_id="O3" value="-22.92" lower_limit="-32.50" upper_limit="-13.50"/>
                    <measurement group_id="O4" value="-18.50" lower_limit="-28.50" upper_limit="-11.00"/>
                    <measurement group_id="O5" value="-13.00" lower_limit="-21.00" upper_limit="-5.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Urticaria Activity Score Response (UAS7=0) Rate at Week 12 Measured Over 7 Days</title>
        <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.
Complete urticaria activity response is defined as UAS7 = 0.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Urticaria Activity Score Response (UAS7=0) Rate at Week 12 Measured Over 7 Days</title>
          <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.
Complete urticaria activity response is defined as UAS7 = 0.</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UAS7=0 Response: at Week 20 Measured Over 7 Days</title>
        <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.
Complete urticaria activity response is defined as UAS7 = 0.</description>
        <time_frame>Week 20</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>UAS7=0 Response: at Week 20 Measured Over 7 Days</title>
          <description>UAS7 is the sum of the HSS7 and the ISS7 scores. The possible range of the weekly UAS7 score is 0 to 42.
Complete urticaria activity response is defined as UAS7 = 0.</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Itch Response (ISS7=0) Rate at Week 12 Measured Over 7 Days</title>
        <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete itch response defined as ISS7 = 0.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Itch Response (ISS7=0) Rate at Week 12 Measured Over 7 Days</title>
          <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete itch response defined as ISS7 = 0.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ISS7=0 Response: at Week 20 Measured Over 7 Days</title>
        <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete itch response defined as ISS7 = 0.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
        <time_frame>Week 20</time_frame>
        <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>QGE031 24 mg s.c. q4w</title>
            <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>QGE031 72 mg s.c. q4w</title>
            <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>QGE031 240 mg s.c. q4w</title>
            <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Omalizumab 300 mg s.c. q4w</title>
            <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>placebo injection subcutaneous every 4 week</description>
          </group>
        </group_list>
        <measure>
          <title>ISS7=0 Response: at Week 20 Measured Over 7 Days</title>
          <description>Itch Severity Score (ISS) is on a scale of 0 to 3. A weekly score (ISS7) is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 to 21.
Complete itch response defined as ISS7 = 0.
Itch Severity Score scale:
0 - None
- Mild (minimal awareness, easily tolerated)
- Moderate (definite awareness, bothersome but tolerable)
- Severe (difficult to tolerate)</description>
          <population>Full analysis set (FAS) included all randomized patients, removing misrandomized patients provided that study drug was not administered. As per protocol and SAP, for the efficacy endpoints at Week 12 or Week 20, only the QGE031 24, 72 &amp; 240 mg, omalizumab 300 mg and placebo arms were analyzed for efficacy comparison between treatment groups.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 44 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>QGE031 24 mg s.c. q4w</title>
          <description>ligelizumab 24 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>QGE031 72 mg s.c. q4w</title>
          <description>ligelizumab 72 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>QGE031 240 mg s.c. q4w</title>
          <description>ligelizumab 240 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="E4">
          <title>Omalizumab 300 mg s.c. q4w</title>
          <description>omalizumab 300 mg injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="E5">
          <title>Placebo s.c. q4w</title>
          <description>placebo injection subcutaneous every 4 weeks</description>
        </group>
        <group group_id="E6">
          <title>QGE031 120 mg s.c. s.d.</title>
          <description>ligelizumab 120 mg injection subcutaneous single dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Colon dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>(862) 778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

